Skip to main content

Table 7 Innate immune cells for cancer immunotherapy

From: Combination strategies to maximize the benefits of cancer immunotherapy

Natural killer cells Stimulatory Activating receptors: NKP30, NKP44, NKG2D, CD16, 2B4
Cytokines: IL-2 and IL-15
Engineered NK cells
Inhibitory ITIM-containing receptors (KIR family, PD1 and TIGIT)
CD94/NKG2A
LIR1
TIM-3
IDO
Dendritic cells Stimulatory cGAS-STING pathway
TLR
Cytokines: GM-CSF, Type I IFN, FLT3L
Inhibitory ITIM-containing receptors (FcγRIIB, etc.)
CD39/CD73/adenosine pathway
IDO
Macrophages Stimulatory CpG oligonucleotide
IFN-γ
TNF-α
IL-12
TLR agonists
Inhibitory ITIM-containing receptors (SIRPα-CD47, SIGLEC-10, etc.)
IL-10, IL-4, IL-13
CCL5, CCL2/CCR2